HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Wahl, R. L.

Tositumomab and ¹³¹I Therapy in Non-Hodgkin’s Lymphoma

Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

View larger version (43K): [in a new window]   FIGURE 1. CD20 expression profile.

View larger version (70K): [in a new window]   FIGURE 2. Rationale for antibody predosing. Image of hot spleen (left) (without predosing) or with cold antibody predosing (right).

View larger version (64K): [in a new window]   FIGURE 3. (A) Rationale for patient-specific dosimetry (fast vs. slow clearance). Comparable area under curve. (B) Actual therapeutic millicuries required to deliver specified total body radiation dose of 65 or 75 cGy (n = 634).

View larger version (36K): [in a new window]   FIGURE 4. Tositumomab and 131I-tositumomab therapeutic regimen.

View larger version (76K): [in a new window]   FIGURE 5. Sample whole-body dosimetric count images after tracer dose, showing localization to left axillary tumor focus. Note otherwise normal biodistribution of radiotracer after 5-mCi dose.

View larger version (26K): [in a new window]   FIGURE 6. Mean and raw platelet count and upper and lower quartile bounds of platelet count, absolute neutrophil count, and hematocrit after tositumomab and 131I-tositumomab therapy.